Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects
Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Arvinas (NASDAQ:ARVN) Lowered to Neutral Rating by The Goldman Sachs Group
Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by The Goldman Sachs Group from a “buy” rating to a “neutral” rating ...
Reviewing Elevai Labs (NASDAQ:ELAB) & Arvinas (NASDAQ:ARVN)
Elevai Labs (NASDAQ:ELAB – Get Free Report) and Arvinas (NASDAQ:ARVN – Get Free Report) are both small-cap multi-sector conglomerates companies, but which is the superior business? We will compare the ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics ...
Endpoints News2h
Up­dates on health agency nom­i­nees; New da­ta from Pfiz­er, Beam; MASH start­up weighs IPO; and more
Trump administration withdraws Dave Weldon's CDC nomination, while Pfizer/Arvinas report mixed breast cancer data and Roche/Zealand Pharma form $5.3B obesity partnership.